A surge in counterfeit prescription pills and emerging synthetic compounds is intensifying the drug crisis in the United States, according to officials testifying before a House Energy and Commerce subcommittee. Lawmakers reviewed a package of 14 bills aimed at curbing illicit drug flows, tightening controls on new substances, and improving treatment access.
The counterfeit pill epidemic
Scott Oulton, a former Drug Enforcement Administration forensic chief, told lawmakers that “the most urgent threat today is counterfeit prescription pills.” These pills are mass-produced by criminal networks with “no quality control or consistency,” even when they appear identical. Two pills that look the same can “contain wildly different amounts of deadly drugs such as fentanyl, nitazenes, xylazine,” according to Oulton’s testimony, highlighting the unpredictability that has driven fatal overdoses. Dennis Lemma, sheriff of Seminole County, Florida, said today’s drugs are “more potent, unpredictable, and deceptive” than in previous decades. Many users believe they are taking legitimate prescription drugs, only to ingest substances laced with fentanyl or other synthetic compounds. In some cases, Lemma warned, “a single dose is fatal.”
Emerging compounds complicate response
One emerging concern is xylazine, a veterinary sedative increasingly found mixed with opioids. Because it is not an opioid, naloxone—widely used to reverse overdoses—“does not reverse its effects,” complicating emergency responses. Another compound gaining attention is a synthetic substance known as 7OH, which is being marketed as a natural product despite significant risks of addiction and overdose. Proposed legislation would classify substances such as xylazine and nitazenes under the Controlled Substances Act. However, some public health experts urged caution, warning that aggressive scheduling can produce unintended consequences. Nabarun Dasgupta, a researcher at the University of North Carolina, noted that restricting one drug can quickly lead to the emergence of another, with xylazine being rapidly replaced by medetomidine in some areas.
Balancing enforcement with treatment
The hearing highlighted a divide in approach, with some lawmakers emphasizing criminal enforcement and supply-side controls while others called for expanded treatment and harm reduction. Public health officials stressed the importance of sustaining gains made in reducing overdose deaths. Yngvild Olsen, a former federal addiction official, said fatalities have declined in recent years but warned that progress could reverse without continued support for treatment. Medications such as methadone and buprenorphine significantly reduce the risk of fatal overdose. Witnesses agreed that the speed of change in the drug market is outpacing current systems, with new tools including wastewater testing helping provide data on drug use trends.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.thehansindia.com/news/international/counterfeit-pills-and-new-chemicals-deepen-us-drug-crisis-1060230